Access at: www. ECRjournal.com Despite improvements in the management of coronary artery disease over the last decades, ischaemic heart disease remains the leading cause of mortality worldwide and the leading cause of premature death. 1,2 Patients with chronic coronary syndromes (CCS) encompass a heterogeneous population, including those with demonstrable coronary artery disease by anatomical testing or evidence of ischaemia, prior MI and prior revascularisation. Most patients with CCS are free of angina, but some may have demonstrable ischaemia (silent ischaemia). 3 Antiplatelet therapy, particularly aspirin, remains the cornerstone of the management of CCS for the prevention of atherothrombotic events. [4] [5] [6] Additional therapies to improve platelet inhibition and reduce ischaemic events have been developed, but are often associated with an increase in bleeding events. P2Y 12 receptor inhibition by clopidogrel alone as a substitute for aspirin failed to improve ischaemic outcomes in the coronary artery disease population, and the combination of clopidogrel and aspirin increased bleeding. 7,8 New P2Y 12 inhibitors, such as prasugrel and ticagrelor, reduced the risk of major cardiovascular outcomes when used for over 1 year after MI, but also increased the risk of bleeding. 9,10 Ongoing trials are evaluating which patients with CCS may benefit most from these new P2Y 12 inhibitors. 11, 12 Vitamin K antagonists (VKAs) have been used for many decades in patients with coronary syndromes for the prevention of atherothrombotic events, showing effectiveness in reducing the recurrence of major cardiovascular outcomes. 13, 14 However, increased bleeding related to a narrow therapeutic index requiring long-term careful monitoring and dose adjustment has resulted in VKAs being replaced by aspirin. 15 Direct-acting oral anticoagulants (DOACs) have a favourable benefit/ risk ratio (i.e. ischaemia/bleeding ratio) and easier use than VKAs, which could impact on the management of CCS, in the same way they DOACs with a reduction of bleedings (HR 0.69;.81]; p<0.001 for non-inferiority and superiority). Edoxaban 60 mg once daily plus a P2Y 12 inhibitor was non-inferior to a VKA regimen on bleeding outcomes (major bleeding or non-major clinically relevant non-major bleeding) after a 12-month follow-up (HR 0.83; 95% CI [0.65-1.05]; p=0.001 for non-inferiority; p=0.1154 for superiority). Meta-analysis of these four trials confirmed the safety of DOACs regarding bleeding outcomes, but showed a trend toward stent thrombosis for dual antithrombotic therapy using DOACs versus triple antithrombotic therapy using VKAs. DOACs may show promise in the management of high-risk patients with chronic coronary syndromes. In these patients, rivaroxaban 2.5 mg twice daily in addition to aspirin was shown to reduce the composite outcome of cardiovascular death, stroke or MI compared to aspirin alone (HR 0.76; 95% CI [0.66-0.86]; p<0.001). All-cause death, cardiovascular death and stroke were also significantly lower. This benefit was at the cost of an increase in non-fatal bleeding.
Direct-acting Oral Anticoagulants in Non-valvular AF and Percutaneous Coronary Intervention
Almost 10% of patients with CCS also have AF. 16, 17 Of those with AF, 25-35% also have a coronary syndrome. [18] [19] [20] Undergo PCI (PIONEER AF-PCI) was the first randomised study to evaluate patients treated with either rivaroxaban or warfarin for NVAF who would also need DAPT after PCI. 21 The primary outcome was safety (major bleeds, minor bleeds or bleeding requiring medical attention) and the secondary outcome was efficacy (composite of cardiovascular death, MI or stroke). Between 2013 and 2015, 2,124 patients with NVAF who had undergone PCI with stent placement were recruited. They were at a low thromboembolic risk (average CHA 2 DS 2 -VASc score 1.6) and without any prior stroke or transient ischaemic attack (TIA) when enrolled. Almost half were known to have CCS. This open-label trial randomised patients in a 1:1:1 ratio to receive:
• Rivaroxaban 15 mg once daily plus single antiplatelet therapy (SAPT) with a P2Y 12 inhibitor (clopidogrel 75 mg once daily, ticagrelor 90 mg twice daily, or prasugrel 10 mg once daily) for 12 months.
• Rivaroxaban 2.5 mg twice daily, with stratification to a prespecified duration of DAPT (for 1, 6 or 12 months) including low-dose aspirin (75-100 mg once daily) plus a P2Y 12 inhibitor (clopidogrel 75 mg once daily, ticagrelor 90 mg twice daily, or prasugrel 10 mg once daily). After stopping aspirin, rivaroxaban was increased to 15 mg once daily (or 10 mg in the event of renal insufficiency) and the P2Y 12 inhibitor was continued at the same dose.
• VKA as the control group, with stratification to a prespecified duration of DAPT (given by each investigator; 1, 6 or 12 months), including low-dose aspirin (75-100 mg once daily) plus a P2Y 12 inhibitor (clopidogrel 75 mg once daily, ticagrelor 90 mg twice daily or prasugrel 10 mg once daily).
Randomisation was done up to 72 hours after the PCI, with conventional DAPT (including loading doses) up to 72 hours. For each group, clopidogrel was the most common P2Y 12 inhibitor, used in >93% of cases (Figure 1) .
At 12 months, the intention-to-treat analysis showed a significant reduction in bleeding for both rivaroxaban regimens compared with the VKA group. The HR for the primary safety composite outcome (including major bleeding, minor bleeding or bleeding requiring medical attention) was lower in the rivaroxaban 15 mg once daily regimen compared with the VKA regimen (HR 0.59; 95% CI [0.47-0.76]; p<0.001). 22 The HR for the primary bleeding outcome was also lower in the rivaroxaban 2.5 mg twice daily group compared to the VKA regimen (HR 0.63; 95% CI [0.50-0.80]; p<0.001). 23 There was no significant difference in the secondary efficacy outcome between the arms and no more in-stent thrombosis in the two rivaroxaban regimens compared with the VKA regimen. 23 Despite being an exploratory and underpowered study, the results of PIONEER-AF suggested an equivalence of rivaroxaban and VKA regimens.
Dabigatran and the RE-DUAL PCI Trial
The non-inferiority Evaluation of Dual Therapy with Dabigatran vs.
Triple Therapy with Warfarin in Patients with AF that Undergo a PCI With Stenting (RE-DUAL PCI) trial evaluated dabigatran in patients requiring oral anticoagulation for NVAF and DAPT for a PCI with stent insertion. 24 In contrast to PIONEER AF-PCI, patients with stroke or TIA over 1 month previously were randomised. They were at a higher thromboembolic risk with a mean CHA 2 DS 2 -VASc score of 3.5.
Between 2014 and 2016, 2,725 patients were enrolled. Nearly half were patients with CCS. This open-label trial randomised subjects to one of three regimens in a 1:1:1 ratio to receive:
• Dabigatran 110 mg twice daily plus SAPT with either clopidogrel 75 mg once daily or ticagrelor 90 mg twice daily for the entire follow-up.
• Dabigatran 150 mg twice daily plus SAPT with either clopidogrel 75 mg once daily or ticagrelor 90 mg twice daily, for the entire follow-up.
• Warfarin, plus DAPT with aspirin <100 mg once daily and either clopidogrel 75 mg once daily or ticagrelor 90 mg twice daily. The duration of aspirin was 1 month for bare-metal stents and 3 months for drug-eluting stents.
Randomisation was done up to 120 hours after the PCI, with conventional DAPT up to 120 hours after the index PCI. Clopidogrel was the most common P2Y 12 inhibitor, used in almost 90% of cases. No prasugrel was used in this trial (Figure 2) . Mean follow-up was 14 months. The primary composite endpoint was the occurrence of major bleeding or clinically relevant non-major bleeding. 25 The intention-totreat analysis showed a significant reduction of bleeding in both 
Apixaban and the AUGUSTUS Trial
The Apixaban Versus Warfarin in Patients with AF and Acute Coronary Syndrome or PCI (AUGUSTUS) trial, enrolled >4,600 patients with NVAF (mean CHA 2 DS 2 -VASc score 3.9) and without severe renal insufficiency within 14 days after an acute coronary syndrome and/or a PCI. 27 They were randomised using a two-by-two factorial design to receive: Main exclusion criteria:
• NVAF requiring a PCI 
ACS = acute coronary syndrome; DOAC = direct oral anti-coagulant; INR = international normalised ratio; NVAF = non-valvular AF; PCI = percutaneous coronary intervention.
Overall 1,506 patients (52% after an acute coronary syndrome and 48%
after elective PCI) were randomised up to 5 days after PCI in two arms. for edoxaban.
The ENTRUST AF-PCI trial was the fourth trial showing the safety of a dual therapy combining a DOAC with a P2Y 12 inhibitor (mainly clopidogrel) on bleeding outcomes. However, this trial -similar to the three previously described -was underpowered to demonstrate a potential efficacy on ischaemic coronary events.
Meta-analysis of the Four Randomised Clinical Trials
A meta-analysis of the four trials (PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS and ENTRUST AF-PCI) assessed the dual antithrombotic therapy using DOACs with SAPT versus triple antithrombotic therapy using VKA with DAPT. 29 The results confirmed the safety of dual antithrombotic therapy with DOAC over triple antithrombotic therapy with VKA on bleeding outcomes with a risk ratio of 0.62 (95% CI [0.47-0.81]; p=0.0005; Figure 5 ). These experimental findings have yet to be translated clinically. In patients with NVAF, rivaroxaban treatment was associated with a lower total and calcified plaque volume evaluated by coronary CT angiography compared with warfarin, which may explain cardiovascular event reduction associated with rivaroxaban treatment. 36 A similar study using apixaban is currently ongoing. 37
Direct-acting Oral Anticoagulants as Secondary Prevention in Chronic Coronary Syndromes The COMPASS Trial
DOACs are easier to use, safer than and as effective as VKAs for thromboprophylaxis in patients with NVAF. Therefore, the question regarding the role of oral anticoagulants in the secondary prevention of atherothrombotic events has been raised.
To date, the only published results in humans are for rivaroxaban. The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial evaluated whether low-dose rivaroxaban alone or in addition to aspirin was safer and more effective than aspirin monotherapy in stable cardiovascular disease. 38 Between 2013 and 2016, this double-blind trial enrolled 27,395 patients with stable cardiovascular disease, including 90% with CCS and 27%
with peripheral arterial disease (PAD). To be enrolled, patients had to be at a high cardiovascular risk. If patients were ≥65 years old, no additional inclusion criteria were needed. Patients <65 years old required the presence of atherosclerosis involving at least two vascular beds or two or more additional risk factors: current smoker, diabetes, moderate chronic renal insufficiency, heart failure or non-lacunar ischaemic stroke (≥1 month previously; Figure 6 ). Patients were randomised in a 1:1:1 ratio to receive one of the following three regimens:
• Rivaroxaban 2.5 mg twice daily + aspirin 100 mg once daily, long term.
• Rivaroxaban 5 mg twice daily, long term.
• Aspirin 100 mg once daily (control).
The study was prematurely stopped by the data safety monitoring board following interim analysis that showed a significant improvement in the primary composite endpoint, as well as all-cause death.
The primary efficacy composite outcome of cardiovascular death, stroke or MI, was significantly lower in the rivaroxaban 2.5 mg twice daily + aspirin group than in the aspirin monotherapy group (4.1% and 5.4%, respectively; HR 0.76; 95% CI [0.66-0.86]; p<0.001). These results were driven by a decrease in cardiovascular death and stroke. The rate of all-cause death was also significantly lower ( Figure 7) . 39 The main safety outcome was major bleeding defined by modified ISTH criteria including all bleeding that led to presentation at an acute care facility or hospitalisation. It was higher in the rivaroxaban -current smoking -diabetes -eGFR <60 ml/min -heart failure -non-lacunar ischaemic stroke ≥1 month
• Haemorrhagic or lacunar ischaemic stroke was no significant difference in the rate of fatal bleeding, intracranial bleeding, or symptomatic bleeding into a critical organ ( Figure 7 ). 39 The subjective net clinical benefit outcome taking into account cardiovascular death, stroke, MI, fatal bleeding or symptomatic bleeding into a critical organ was in favour of rivaroxaban + aspirin therapy (HR 0.80; 95% CI [0.70-0.91]; p<0.00.1; Figure 7 ) compared to aspirin alone. 39 However, the benefit/risk ratio was unfavourable for rivaroxaban 5 mg twice-daily monotherapy compared with aspirin monotherapy. There was no significant improvement in the efficacy outcome but there was a significant increase in major bleeding, advocating against this strategy ( Figure 7 ). 39 The substudy of patients with CCS in the COMPASS trial, comprising 90.6% of the entire population and performed using the same design,
showed similar results. 40 Therefore, despite early termination -possibly overestimating the treatment effect -the findings of the COMPASS study suggested that rivaroxaban 2.5 mg twice daily may become an additional treatment for CCS in selected patients at high ischaemic risk.
The COMMANDER HF Trial
Decompensated heart failure is associated with an activation of thrombin-related pathways. Thus, patients with CCS with worsening heart failure may be a subpopulation that benefits from the addition 
Direct-acting Oral Anticoagulants in International Guidelines
The 2019 ESC Guidelines for the diagnosis and management of CCS provide the following recommendations: 28 • When oral anticoagulation is initiated in a patient with NVAF, a DOAC is recommended in preference to a VKA (recommendation IA).
• Aspirin 75-100 mg daily (or clopidogrel 75 mg daily) may be considered in addition to long-term oral anticoagulant therapy in patients with NVAF and CCS at high risk of recurrent MI (prior MI, multivessel disease, diabetes, chronic kidney disease with estimated glomerular filtration rate <60 ml/min/1.73m 2 , PAD) NVAF, but not high risk of bleeding (recommendation IIaB).
• For PCI in patients with DOAC, it is recommended that periprocedural aspirin and clopidogrel are administered to patients undergoing PCI (recommendation IC).
• After PCI, in patients eligible for a DOAC, it is recommended that a DOAC (apixaban 5 mg twice daily, dabigatran 150 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 20 mg once daily) is used in preference to a VKA in combination with antiplatelet therapy (recommendation IA).
• After PCI, when rivaroxaban or dabigatran are used and concerns about high bleeding risk prevail over concerns about stent thrombosis or ischaemic stroke, lower DOAC doses should be considered for the duration of concomitant SAPT or DAPT as follows:
rivaroxaban 15 mg once daily, dabigatran 110 mg twice daily (recommendation IIaB).
• After PCI, early cessation (≤1 week) of aspirin and continuation of dual therapy with an oral anticoagulant and clopidogrel should be considered if the risk of stent thrombosis is low, or if concerns about bleeding risk prevail over concerns about the risk of stent thrombosis irrespective of the type of stent used (recommendation IIaB).
• After PCI, triple therapy with aspirin, clopidogrel, and an oral anticoagulant for ≥1 month should be considered when the risk of stent thrombosis outweighs the bleeding risk, with the total duration (≤6 months) decided according to assessment of these risks (recommendation IIaC).
• The use of ticagrelor or prasugrel is not recommended as part of triple antithrombotic therapy with aspirin and an oral anticoagulant (recommendation III).
Conclusion
In patients with NVAF treated with DOACs, switching to a VKA regimen is not required when a PCI is needed. Short-term triple antithrombotic therapy (DOAC + aspirin + clopidogrel) up to 3 months followed by dual antithrombotic therapy (DOAC + clopidogrel) up to 1 year seems to be the best strategy, compared with triple antithrombotic therapy (VKA + aspirin + clopidogrel).
DOACS may become an accepted secondary prevention therapy as suggested by the COMPASS study. However, before DOACs become a cornerstone of the management of selected patients with CCS, further studies are needed to address some issues. Identifying which patients will derive the highest ischaemic benefit with the lowest haemorrhagic risk needs to be determined. The additional benefit on the recurrence of major cardiovascular events and death with rivaroxaban in such patients is offset by the higher rate of bleeding events. In that case patients should not move to this strategy, particularly if they are stable, asymptomatic and risk the occurrence of both major and minor bleeding. The potential use of DOACs in combination with new antiplatelet drugs is not known.
Moreover adherence may be challenging because of the need for a twice-daily dosing regimen. All these factors will have to be discussed individually with each patient for optimal individualised care that improves both outcomes and quality of life (i.e. taking into consideration the ischaemia/bleeding ratio).
Another issue will be the cost of this additional new therapy. Given the high number patients potentially eligible for low dose rivaroxaban in addition to aspirin, 42 the clinical/cost ratio compared with the low cost of the aspirin alone will have to be evaluated. This is particularly relevant given that the absolute risk reduction is quite low (the number needed to treat to avoid one primary outcome is 77).
